Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled ascending-dose study of inhaled SPL84 in cystic fibrosis with the CFTR 3849+10kb C>T mutation
MOH_2024-08-27_013604Phase 2Not yet recruiting
- Sponsor
- SpliSense
- Start
- Aug 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing SPL84 with Placebo (2 arms). Primary endpoints: Safety and tolerability of multiple doses of SPL84, Pharmacokinetics of SPL84 and 1 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
SPL84
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on MOH_2024-08-27_013604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-08-27_013604.